Levothyroxine Recall: What Patients Need to Know About the Nationwide Alert
The American Thyroid Association (ATA) has issued an important alert regarding a voluntary recall of levothyroxine sodium tablets, a commonly prescribed medication for hypothyroidism. On July 13, Major Pharmaceuticals initiated the recall after the U.S. Food and Drug Administration (FDA) determined that certain batches of the tablets were subpotent, meaning they contain less active ingredient than labeled. This could result in patients receiving a lower dose than prescribed, potentially affecting thyroid hormone levels.
The recall covers 12 package configurations sold under the Major and Cardinal brand names. These include individual packs of 10 tablets and boxes containing 10 blister packs. The affected products were distributed nationwide starting in January 2025. According to the FDA, Major Pharmaceuticals was responsible for packaging and distributing the medication, with Cardinal Health handling distribution for part of the supply chain.
In a letter sent to retailers, Major Rugby—the pharmaceutical manufacturer behind the products—stated that taking the recalled medication “is not likely to cause adverse health effects”. However, patients are urged to return their medicine to the point of purchase. The ATA emphasizes that patients should not stop taking their medication without consulting a healthcare provider, as untreated hypothyroidism can lead to serious health issues.
Patients who have purchased levothyroxine from Major or Cardinal brands are advised to check their prescription bottles for the recalled lot numbers. The ATA recommends contacting your pharmacist or healthcare provider for guidance on obtaining a replacement. For more information, visit the ATA website or the FDA’s recall page. Stay informed and ensure your thyroid medication is safe and effective.
Shimanta Das 
